Cancer deaths have remained a heavy burden in Japan, thus cancer screening has been anticipated to be a practical strategy for reducing mortality from cancers. The Basic Plan to Promote Cancer Control Program published in 2006 stated that evidence-based cancer screening is required. At the conception of national cancer screening programs, there were no cancer screening assessments. From 1998 to 2001, Hisamichi formed committees for the assessment of cancer screening and published three reports. These reports were the cornerstone in assessing primary studies of cancer screening in Japan which served as a stimulus for the development of cancer screening guidelines. Since 2003, research groups funded by the National Cancer Center have developed cancer screening guidelines based on established methods in reference to international standards. Screening guidelines for the following cancers have been published: gastric, colorectal, lung, prostate, cervical and breast cancers. Recommendations for screening are made following assessment of the balance of benefits and harms. The recommendation has been divided for population-based screening and opportunistic screening. New screening techniques with insufficient evidence have been suggested to further undergo research. The national committee has continued to appraise their evidence for cancer screening based on established guidelines and has discussed implementation problems. The screening methods for breast and gastric cancers have been revised based on cancer screening guidelines. Cancer screening guidelines have increasingly contributed to the promotion of evidence-based cancer screening for national programs. To provide appropriate cancer screening evidence, additional studies to further improve the methodology for guideline development are warranted.
Introduction
Cancer has remained a heavy burden worldwide, with 14.1 million new cancer cases and 8.2 million deaths in 2012 (1) . In Japan, the leading causes of cancer death in 2015 were lung cancer in men and colorectal cancer in women (2) . Therefore, cancer control has been adopted as the main policy for reducing mortality from cancer. To achieve this goal, cancer screening in particular has been anticipated as a practical strategy. Breast and cervical cancer screenings have already been introduced in most of developed countries and have been instituted in developing countries (3, 4) . In Japan, screenings for gastric, colorectal, lung, breast and cervical cancers have been conducted. Deaths from these cancers have decreased or flattened in the last two decades (2) . However, the proportion of deaths from five cancers targeted by cancer screenings remained at 50.5% in 2015 (2) . In 2006, the Cancer Control Act was approved in Japan and then the Basic Plan to Promote Cancer Control Program was subsequently developed, which clearly defined the goal of reducing mortality from cancer by 20% (5) . In these programs, cancer screening plays significant role in reducing mortality from cancer. Therefore, it is clearly indicated that evidence-based cancer screening is required.
Gastric and cervical cancer screenings started in some parts of local municipalities in the 1960s and were subsequently introduced nationwide (6) . After the Second World War, gastric cancer became a heavy burden for the Japanese people. In 1960, the gastric cancer mortality rate adjusted to the world population was 53.0/100 000, which is a 5-fold increase compared with that in 2015 (2) . Photofluorography for upper gastrointestinal series with barium meal (UGI) was originally developed in Japan and adopted for gastric cancer screening. In 1960, the cervical cancer mortality rate adjusted to the world population was 4.0/100 000, which is twice compared with that in 2015 (2) . Although cervical cancer screening has been introduced in Finland since the 1960s, there were nonexperimental studies to evaluate reduction of incidence of invasive cancer (7) . In 1983, national cancer screening programs were introduced based on the Health Service Law for the Aged (Table 1) . Initially, gastric and cervical cancer screenings were started, and then lung, colorectal and breast cancer screenings followed. However, at the introduction of these cancer screenings, there was no discussion about the scientific evidence of cancer screenings except for colorectal cancer screening. Most people including physicians simply believed that the early detection of cancer directly prevented cancer death.
In 1976, the Canadian Task Force on Preventive Health Care (CTFPHC) developed clinical practice guidelines including cancer screening and reported their assessment results (8) . The CTFPHC was developed by the Conference of Deputy Ministers of Health of the ten Canadian provinces. Although the CTFPHC was disbanded in 2005, it was re-established with the support of the Public Health Agency of Canada in 2010. On the other hand, the US Preventive Services Task Force (USPSTF) was established in 1984 (9) . Since 1998, the Agency for Healthcare Research and Quality (AHRQ) has been authorized by the U.S. Congress to convene the Task Force. Task Force members are appointed by the Director of AHRQ. The task forces have published guidelines for clinical preventive services including cancer screenings. Their reports had been circulated worldwide which led to the recognition of the necessity for the assessment for primary studies of cancer screenings. These developments have been mainly supported by the dissemination of evidencebased medicine. After the introduction of national cancer screening programs, the results of randomized-controlled trials for breast and colorectal cancer screenings have been reported continuously from western countries. Thereafter, the necessity of conducting evaluation studies became increasingly recognized by researchers and physicians whose work was related to cancer screening, paving the way for observational studies, particularly case-control studies. Prior to the introduction of colorectal cancer screening using fecal occult blood testing as a national program, the results of case-control studies conducted in Japan were referred to.
In this article, the history of development of cancer screening guidelines and the establishment of related policies are revisited to gain important insights for further development and improvement.
First assessment of cancer screening
From 1998 to 2001, Hisamichi formed committees for the assessment of cancer screening and published three reports (10) (11) (12) . At that time, the procedure for developing clinical practice guidelines was not yet established. Moreover, the assessment in these reports was not systematic and was insufficient to serve as reference for the establishment of the current standard of guideline development. However, these reports served as the cornerstone for assessing studies of cancer screening in Japan and triggered the subsequent development of cancer screening guidelines.
In the final report of Hisamichi, the outlines consisted of both basic information (e.g., textbook) and profiles of famous studies for cancer screenings (12) . Experts of cancer screening who were mainly physicians were purposely invited by the committee. There were no specialists regarding the development of clinical practice guidelines. The frameworks were defined to assess the efficacy/effectiveness of cancer screening. However, the results of cancer screening conducted in Japan were also reported, which were not related to the assessment of primary studies. The main outcomes were mortality reduction from targeted cancers and sensitivity and specificity of the screening method, stage shift of screen-detected cancers, survival rates of screen-detected cancers, and economic evaluation in reference to related studies. Although a systematic research was conducted on PubMed by participants in the development of these reports (personal communications), there was no record of search engines or search keywords in these reports. There were also no criteria for inclusion and exclusion of studies. Therefore, the results of the literature search and assessment could not be reproduced. Harms of cancer screening were included in the second and final reports. The recommendations were mainly based on evidence of reduction in mortality from the targeted cancers, but the final decisions were made comprehensively. Although a summary was shown in a table, the judgment process was unclear. In the final report, the results referred to the level of evidence in the second version criteria developed by the USPSTF (13) . Positive evidence was found as follows: Pap smear for cervical cancer screening, chest X-P and sputa cytology for a high-risk group for lung cancer screening, fecal occult blood testing for colorectal cancer screening, upper gastrointestinal series with barium meal for gastric cancer screening, mammography with clinical breast examination for breast cancer screening, and hepatitis antibody for hepatocellular carcinoma screening (Table 2 ). Other strategies which had been used for cancer screening were also assessed, but these strategies did not show positive results.
The results of these reports had a big impact on physicians involved in cancer screening because most of them believed that an increase in the early detection of cancer was sufficient evidence. The results have been referred to the national committee since 2000 and the evidence was reassessed based on these results (Table 1) . However, the committees formed by Hisamichi were temporary, and there were no plans to continue the assessments of cancer screening. Based on these experiences, Hisamichi proposed the continuation of assessments and recommend their adoption in policy making for national cancer screening programs.
Development of cancer screening guidelines in Japan
The responsibility of developing cancer screening guidelines has been subsequently turned over to the National Cancer Center (NCC) of Japan. NCC has provided research groups funding for the development of cancer screening guidelines. The main members of these research groups have been physicians involved in cancer screenings and researchers with experience in conducting primary studies to evaluate the effectiveness of cancer screenings. Researchers in these related fields were also included as members; public health, epidemiology, clinical practice guideline, systematic review, and health technology assessment. All research group members are shown in Appendix.
As the guideline development method was not specifically established in the reports of Hisamichi, the new method was defined and formulated on the basis of other guidelines including the USPSTF and Scottish Intercollegiate Guidelines Network (SIGN) (14) . For systematic literature search, analytic framework was developed by referring to the USPSTF method (15) . An analytic framework is a tool for the guideline development of the specific linkages to evidence that must be present for a preventive service to be considered effective (15) . An example of an analytic framework for breast cancer screening in the Japanese cancer screening guidelines is shown in Fig. 1 (16) . Clinical questions are made for each stage on the analytic framework. The best available evidence to answer the clinical questions is searched by systematic review. Harms of cancer screening are also included in the clinical questions on the analytic framework. Since information on these items has been insufficient, a case report could be occationally an important information resource.
Literature search is usually performed using several search engines including those of PubMed and Embase. First, titles and abstracts are reviewed and candidate articles are selected. Then, the quality of the studies is assessed using checklists. The level of evidence has been defined according to the SIGN criteria (17) . The feature of the SIGN criteria for the level of evidence was the combination of study design and quality. Finally, these pieces of information are connected and assessed as a body of evidence. If there is no direct evidence to evaluate mortality reduction from the targeted cancer, the chain of evidence is assessed.
Recommendations are made according to the balance of benefits and harms based on evidence. The recommendation grade of the USPSTF (15) has been adopted. In addition, the recommendation has been divided for population-based screening and opportunistic screening because the goals of these screenings are different. The aim of population-based screening has performed to reduce mortality from targeted cancer as a public health policy (14) . A typical example of population-based screening is community-based screening. However, the Japanese system has been insufficient as an organized screening like Nordic countries. Basically, all municipalities in Japan have referred to the principal policy of the national government, but they can easily modify their method of providing cancer screening programs. Multiphasic health check-ups with cancer screening have been common in opportunistic screening, but the providing system was different from that of population-based screening. Considering various situation, recommendations for both screenings are thus included in cancer screening guidelines (14) .
Since 2003, guidelines for the following cancer screening have been developed: gastric, colorectal, lung, prostate, cervical, and breast cancers. Evidence reports for the screening of hepatitis and hepatocellular carcinoma, and gastric cancer have also been developed (16, (18) (19) (20) (21) . The guidelines for gastric cancer screening were Table 3 . The results of these cancer screening guidelines have initiated discussions about the evaluation of new techniques for cancer screenings. The main problems in terms of conflicts were insufficient understanding of evidence-based medicine and the basic concepts of cancer screening as a public health policy. As opportunistic screening has been commonly performed in Japan, the difference between population-based screening and opportunistic screening has not been clearly discriminated. In opportunistic screening, a new technique is easily introduced without any assessment. Therefore, most physicians have come to believe that new techniques can be easily introduced in population-based screening because this increases the early detection of cancer.
To address the above-mentioned conflicts, the research component has been suggested and added. Even if a new technique is assessed as not having sufficient evidence to warrant its recommendation, there is a possibility for the cancer screening technique to be introduced upon accumulation of evidence. In the introduction of a new cancer screening technique, a step-by-step evaluation is required. In this connection, Pepe et al. proposed a strategic process for biomarker development for cancer screening (22) . After validation in the clinical setting, additional studies on cancer screening are required. Notably, when the first guidelines for gastric cancer screening were developed, there was insufficient evidence regarding the effectiveness of endoscopic screening for gastric cancer (21) . Although studies evaluating reduction of mortality from gastric cancer by endoscopic screening have gradually accumulated in Japan, most studies still have insufficient evidence because of the small sample size and short follow-up period (23) (24) (25) . However, case-control studies conducted in Korea and Japan have ascertained the reduction of mortality from gastric cancer by endoscopic screening (26, 27) . Thus, the recommendation can be revised based on these results. The conduct of gastric cancer screening serves as a good opportunity for the integration of cancer screening guidelines and promotion of primary studies for introducing a new screening technique.
Cancer screening guidelines and policy making
At the initial stage of the development of national cancer screening programs, assessments of the cancer screening were not carried out. This had led to the misconception that new technique for cancer screening can be easily introduced if the early detection of cancer can be achieved. This, however, has the possibility of predominantly causing harms. A good example is neuroblastoma screening in Japan, the only country which has performed such screening since 1984 (28) . After the introduction of neuroblastoma screening in Japan, mortality reduction from neuroblastoma in children younger than 2 years of age has been reported (29) . However, in 2002, studies from Germany and Canada showed no mortality reduction from neuroblastoma screening (30, 31) . In 2003, the Japanese government formed a committee to assess evidence regarding the effectiveness of neuroblastoma screening, and came to a decision to halt the screening (28) . This incident became known as the failure of a no evidence-based policy across the world. Unfortunately, such screening has been continued in some local municipalities in Japan until not long ago. Through all of these experiences, the necessity of cancer screening assessments has been gradually recognized before the introduction of cancer screening. On the other hand, the reports of Hisamichi were cited in the national committee to ascertain the evidence regarding the efficacy/effectiveness of cancer screenings (Table 1) . Cervical cancer screening using cytology has been continued based on the results of these reports. Breast cancer screening has been modified from clinical breast examination alone to mammography together with clinical breast examination.
From these experiences, the necessity of continuous guideline development has been recognized to achieve effective assessment of cancer screening programs (Table 1) . Evidence regarding the efficacy/ effectiveness of cancer screening has been ascertained on cancer screening guidelines. The national committee has continued to appraise evidence regarding efficacy/effectiveness of cancer screening based on cancer screening guidelines and discussed implementation problems. Subsequently, evidence-based cancer screening could be provided continuously. Recently, the screening methods for breast and gastric cancers have been changed based on the cancer screening guidelines. For breast cancer screening, Hisamichi recommended only mammography with clinical breast examination (12) . The guidelines for breast cancer screening, however, recommended mammographic screening with and without clinical breast examination (16) . Evidence of mortality reduction from breast cancer was previously ascertained from a meta-analysis of mammographic screening with and without clinical breast examination (32) . As a new screening method based on the guidelines, endoscopic examination has been recommended by the national government (18) . As a result, the national committee suggested the establishment of the quality assurance system of endoscopic screening. Thereafter, an academic society developed a manual for quality assurance for support (33) . Thus, cancer screening guidelines are presently considered as a tool for developing evidence-based policies for national cancer screening programs.
To promote evidence-based cancer screening, a close and active collaboration between the NCC and the national committee should be maintained (Fig. 2) . To this end, the NCC has formed a research group and has maintained a management office for systematic review and guideline development. The role of this management office is similar to that of the Agency for Healthcare Research and Quality (ARHQ) for the USPTSF (9); however, its role has remained passive to date. The national committee is responsible for reviewing the national cancer screening programs and discusses appropriate methods in reference to the cancer screening guidelines. To reflect the citizens' voice, cancer screening has often been discussed in the National Council for Promotion of Cancer Control. Through these processes, evidence-based cancer screenings have been implemented as national programs. Thus, cancer screening guidelines have become a significant and necessary instrument for developing evidence-based policies for cancer screening programs in Japan.
Future perspectives
Over the last 15 years of the development of cancer screening guidelines, there have been important advances in research regarding clinical practice guidelines. In 2011, the Institute of Medicine (IOM) changed the definition of clinical practice guidelines and suggested the method for guidelines development and systematic review (34, 35) . The new definition showed a clear distinction for clinical practice guidelines. In the guideline development, the balance of benefits and harms should always be taken into consideration (35) . The Grading of Recommendation Assessment, Development and Evaluation (GRADE) system has also published a method for assessing the quality of evidence and has made a recommendation based on the balance of benefits and harms (36) . Although this concept has been widely accepted, the measurement of net benefits cannot be easily performed and it requires the actual method to be in line with the recommendations. The USPSTF used a decision model to assess the balance of benefits and harms, as well as to define the appropriate method, target age group, and screening interval (37) (38) (39) . The National Institute of Health and Care Excellence (NICE) has conducted cost-effectiveness analysis for guideline development (40) . Even if sensitivity analysis is performed, the results by modeling approach remains uncertainty because the results are easily affected by the parameter used. Recently, multiple criteria decision analysis (MCDA) has been adopted in healthcare settings, particularly in resource allocation and priority settings (41, 42) . MCDA may be one of the solutions for making recommendations in guideline development that is based on the balance of benefits, harms and cost.
Guidelines for cancer screening can also serve as a cornerstone for evidence-based policy making. Therefore, a neutral stance and an adequate methodology are always required. After the change of Figure 2 . Policy making for evidence-based cancer screening for national programs. The National Cancer Center (NCC) has formed a research group and has maintained a management office for systematic review and guideline development. The national committee is responsible for reviewing the national cancer screening programs and discusses appropriate method in reference to the cancer screening guidelines. To reflect the citizens' voice, cancer screening has been often discussed in the National Council for Promotion of Cancer Control. Thereafter, evidence-based cancer screenings have been implemented as national programs. NCC, National Cancer Center; MHLW, Ministry of Health, Labour and Welfare.
definition by IOM, a systematic review group and a guidelines development group were distinctly divided (34) . Previously, some members joined in a systematic reviewer group. However, all members could participate in the discussion for making recommendations for cancer screening guidelines. In this situation, there is a possibility of the assessment results being distorted because the level of evidence is directly affected by the recommendation. For instance, in the development of prostate cancer screening guidelines, urologists overestimated the results of the European study of prostate cancer screening and underestimated that of the American study because positive results would mean a recommendation for prostatespecific antigen (PSA) screening. Maintaining the independence of the systematic review group from the guideline development group can avoid such misleading.
The IOM has also emphasized the importance of proper selection of the members of the systematic review and guideline development groups (34) . During the start of the guidelines development, most members have experience with primary studies of cancer screening. They were therefore considered as preferable resource persons because of their sufficient knowledge of cancer screening. However, from the perspective of academic conflicts, these members are not suitable members at present. In fact, guideline development and systematic review have become their own original and individual fields because of their specialty. This indicates that specialists for systematic review and guideline development are required for cancer screening guidelines. Because such specialists have long been lacking in Japan, their development should be seriously considered. Clinical practice guidelines have also been changed in term of concept, and a method according to social requirements has been adopted. Therefore, participation of lay people should also be included to reflect citizens' voice in cancer screening guidelines (34) .
Recently, the topics for cancer screening have focused on the target age group and screening interval. Although evidence is still insufficient for these issues, the cancer screening guidelines should also be designed to meet the requests from the national committee and find the best available evidence and provide solutions. On the other hand, the limitation of available evidence should be clearly shown. To provide appropriate evidence of efficacy/effectiveness of cancer screening, additional studies involving a more sophisticated methodology for guideline development are required. Thus far, cancer screening guidelines have been effectively contributed to the promotion of evidence-based cancer screening for national programs. Further advancement has been anticipated towards the promotion of evidence-based policy making.
Conclusion
Cancer screening guidelines have been developed in Japan in reference to the standardized method. To date, screening guidelines for gastric, colorectal, lung, prostate, breast and cervical cancers have been published over the last 15 years. Overall, these cancer screening guidelines have effectively contributed to promoting evidencebased cancer screening for national programs in Japan. 
